MEI Pharma Inc Cash Flow Conversion Efficiency
MEI Pharma Inc cash flow conversion efficiency. Based on the latest financial reports, MEI Pharma Inc (MEIP) has a cash flow conversion efficiency ratio of -0.145x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.46 Million) by net assets ($16.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MEI Pharma Inc (2003–2025)
Cash flow conversion efficiency of MEI Pharma Inc from 2003 to 2025. This chart illustrates how MEI Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MEI Pharma Inc (MEIP) stock price for real-time trading data and today's change.
MEI Pharma Inc Cash Flow Conversion Ratio Explained
MEI Pharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MEI Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MEI Pharma Inc ranked by their cash flow conversion efficiency. Also see MEI Pharma Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CLERHP Estructuras S.A
MC:CLR
|
-0.061x |
|
Tamil Nadu Newsprint & Papers Limited
NSE:TNPL
|
-0.022x |
|
Vranken-Pommery Monopole Société Anonyme
PA:VRAP
|
-0.107x |
|
Western Carriers India Ltd
NSE:WCIL
|
-0.020x |
|
Farcent Enterprise Co Ltd
TW:1730
|
0.058x |
|
SaltX Technology Holding AB
ST:SALT-B
|
-0.078x |
|
Asia Pacific Satellite Inc
KQ:211270
|
0.011x |
|
The Hi-Tech Gears Limited
NSE:HITECHGEAR
|
0.043x |
Annual Cash Flow Conversion Efficiency for MEI Pharma Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of MEI Pharma Inc from 2003 to 2025. Review how much free cash does MEI Pharma Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $16.93 Million | $-20.84 Million | -1.231x | +19.46% |
| 2024-06-30 | $33.02 Million | $-50.47 Million | -1.529x | +28.28% |
| 2023-06-30 | $24.62 Million | $-52.48 Million | -2.131x | -129.18% |
| 2022-06-30 | $52.41 Million | $-48.75 Million | -0.930x | -20.35% |
| 2021-06-30 | $41.36 Million | $-31.96 Million | -0.773x | -276.44% |
| 2020-06-30 | $78.22 Million | $34.26 Million | 0.438x | +171.35% |
| 2019-06-30 | $47.93 Million | $-29.42 Million | -0.614x | -45.41% |
| 2018-06-30 | $50.46 Million | $-21.30 Million | -0.422x | -715.66% |
| 2017-06-30 | $50.84 Million | $3.49 Million | 0.069x | +115.99% |
| 2016-06-30 | $41.65 Million | $-17.86 Million | -0.429x | +8.68% |
| 2015-06-30 | $59.79 Million | $-28.07 Million | -0.469x | -9.07% |
| 2014-06-30 | $45.19 Million | $-19.45 Million | -0.430x | -49.43% |
| 2013-06-30 | $34.87 Million | $-10.04 Million | -0.288x | +81.29% |
| 2012-06-30 | $4.60 Million | $-7.08 Million | -1.540x | +57.51% |
| 2011-06-30 | $1.79 Million | $-6.50 Million | -3.624x | -166.59% |
| 2010-06-30 | $7.38 Million | $-10.03 Million | -1.359x | -95.94% |
| 2009-06-30 | $15.21 Million | $-10.55 Million | -0.694x | +0.23% |
| 2008-06-30 | $16.54 Million | $-11.50 Million | -0.695x | +11.18% |
| 2007-06-30 | $13.78 Million | $-10.79 Million | -0.783x | +21.31% |
| 2006-06-30 | $9.13 Million | $-9.09 Million | -0.995x | -194.53% |
| 2005-06-30 | $16.52 Million | $-5.58 Million | -0.338x | +2.78% |
| 2004-06-30 | $22.94 Million | $-7.97 Million | -0.347x | -11.98% |
| 2003-06-30 | $5.93 Million | $-1.84 Million | -0.310x | -- |
About MEI Pharma Inc
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, … Read more